Marksans Pharma Limited

rs,

February 11, 2025 BSE Limited Corporate Relation Department Phiroze Jeejeeboi Towers, Dalal Street, Mumbai - 400001. Scrip Code: 524404 Dear Sir/Madam, National Stock Exchange of I

16.3%

mentary “We are delighted to announce an all-time high quarterly PAT, driven by robust growth of 16.3% YoY in Q3 revenue. Revenue growth was led by the US region, which witnessed 37% YoY growth, follow

37%

obust growth of 16.3% YoY in Q3 revenue. Revenue growth was led by the US region, which witnessed 37% YoY growth, followed by UK, which improved during the quarter. Improved product mix and softer raw

279bps

mix and softer raw material prices compared to the previous year led to gross margin expansion of 279bps YoY. We witnessed some headwinds in terms of EBITDA margin due to our investments in the acquired

₹ 682

.” Mark Saldanha M A N A G I N G D I R E C TO R A N D C E O Q3 FY25 9M FY25 Operating Revenue ₹ 682 cr +16.3% YoY Revenue ₹ 560.0 cr +15.2% YoY Operating Revenue ₹ 1,914 cr +18.4% YoY EBITDA ₹ 13

₹ 560.0

N G D I R E C TO R A N D C E O Q3 FY25 9M FY25 Operating Revenue ₹ 682 cr +16.3% YoY Revenue ₹ 560.0 cr +15.2% YoY Operating Revenue ₹ 1,914 cr +18.4% YoY EBITDA ₹ 139 cr +4.3% YoY EBITDA ₹ 403 cr

15.2%

C TO R A N D C E O Q3 FY25 9M FY25 Operating Revenue ₹ 682 cr +16.3% YoY Revenue ₹ 560.0 cr +15.2% YoY Operating Revenue ₹ 1,914 cr +18.4% YoY EBITDA ₹ 139 cr +4.3% YoY EBITDA ₹ 403 cr +15.5%

₹ 1,914

9M FY25 Operating Revenue ₹ 682 cr +16.3% YoY Revenue ₹ 560.0 cr +15.2% YoY Operating Revenue ₹ 1,914 cr +18.4% YoY EBITDA ₹ 139 cr +4.3% YoY EBITDA ₹ 403 cr +15.5% YoY EBITDA EBITDA Margin 20.4%

18.4%

rating Revenue ₹ 682 cr +16.3% YoY Revenue ₹ 560.0 cr +15.2% YoY Operating Revenue ₹ 1,914 cr +18.4% YoY EBITDA ₹ 139 cr +4.3% YoY EBITDA ₹ 403 cr +15.5% YoY EBITDA EBITDA Margin 20.4% -234 bps

₹ 139

682 cr +16.3% YoY Revenue ₹ 560.0 cr +15.2% YoY Operating Revenue ₹ 1,914 cr +18.4% YoY EBITDA ₹ 139 cr +4.3% YoY EBITDA ₹ 403 cr +15.5% YoY EBITDA EBITDA Margin 20.4% -234 bps YoY ₹ 109.6 cr +0

4.3%

3% YoY Revenue ₹ 560.0 cr +15.2% YoY Operating Revenue ₹ 1,914 cr +18.4% YoY EBITDA ₹ 139 cr +4.3% YoY EBITDA ₹ 403 cr +15.5% YoY EBITDA EBITDA Margin 20.4% -234 bps YoY ₹ 109.6 cr +0.1% YoY

₹ 403

₹ 560.0 cr +15.2% YoY Operating Revenue ₹ 1,914 cr +18.4% YoY EBITDA ₹ 139 cr +4.3% YoY EBITDA ₹ 403 cr +15.5% YoY EBITDA EBITDA Margin 20.4% -234 bps YoY ₹ 109.6 cr +0.1% YoY EBITDA Margin 21.0

“New Manufacturing facility acquired from Teva Pharma in Goa • Scalable capacity with a plan to double the existing Indian capacity from 8bn units per annum • Manufacturing site is spread across 47,597 sq.”

“• Plan to manufacture tablets, ointments, liquids and creams AC C R E D I TAT I O N S *New acquired Teva Pharma facility has scalable capacity to 8bn units p.a.”

“• Our OTC segment grew at CAGR of 17% (from FY17-FY24).”

“Majority of revenue in OTC comes from manufacturing and selling store brands for key retailers in key regions • Marksans is the most preferred and growing low-cost store brand manufacturing partner 02 02 03 04 Capacity expansion • Aim to scale the newly acquired TEVA unit’s capacity to 8bn units p.a.”

“Evaluating acquisitions in Europe region for front-end presence 32 We’ve Delivered What We Promised Marksans Guidance How have we performed?”

“Revenue guidance of ₹ 2,000 cr EBITDA margin guidance of 20% Focus on expanding OTC business – ~3.6x revenue growth since 2017 Disciplined capital allocation approach - Effectively utilizing the cash through buyback, dividends, targeted acquisitions and capacity expansion Achieved Achieved Achieved Achieved 33 Growth: FY25 and Beyond Disciplined efforts to become future ready Growth FY25 and Beyond • Doubling low-cost manufacturing capacity in India from 8bn to 16bn units.”

Total Capacity

1

For more information please contact

1

Total Capacity

26 bn units p.a.* Manufacturing Facility in Southport, UK • Manufactures non-sterile liquids, ointments and powder sachets UK • Supplies to UK, West Africa & Middle East • Spread across 7,300 sq. mt. C A PAC I T Y 2 bn bottles p.a. 1 bn tubes p.a. 1 bn sachets p.a. AC C R E D I TAT I O N S USA INDIA Manufacturing Facility in Farmingdale, USA • Manufactures hard gels, tablets and capsules • Spread over an area of 7000 sq. mt. • "Made in the USA” product offering • Added incremental packaging lines CAPACITY ACCRE DI TAT I O NS 6 bn tablets and hard capsules p.a. Existing Manufacturing facility in Goa • Manufactures Capsules & Tablets • One of the biggest manufacturing facilities in Asia • Fully-automated unit spread over 18,000 sq. mt. campus • Generic pharmaceuticals manufactured from this facility are exported across the globe CAPACITY ACCRE DI TAT I O NS 2.4 bn softgel and hard gelatin capsules p.a. 6 bn solid tablets p.a. New Manufacturing facility acquired from Teva Pharma in Goa •

For more information please contact

Jitendra Sharma (CFO) Marksans Pharma Ltd. Tel: +91 22 4001-2000 jitendra@marksanspharma.com Corporate Office 11th Floor Grandeur, Off Veera Desai Road, Opp Gundecha Symphony, Andheri (W), Mumbai – 400 053, Maharashtra - India © 2025 Marksans Pharma Ltd., All Rights Reserved. “Marksans Pharma” and The Marksans Pharma Logo are trademarks of Marksans Pharma Limited. In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole on or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.